HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation.

Abstract
The physiologic role of the mu opioid receptor (MOR) in gut nociception, motility, and secretion is well established. To evaluate whether MOR may also be involved in controlling gut inflammation, we first showed that subcutaneous administration of selective peripheral MOR agonists, named DALDA and DAMGO, significantly reduces inflammation in two experimental models of colitis induced by administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or peripheral expansion of CD4(+) T cells in mice. This therapeutic effect was almost completely abolished by concomitant administration of the opioid antagonist naloxone. Evidence of a genetic role for MOR in the control of gut inflammation was provided by showing that MOR-deficient mice were highly susceptible to colon inflammation, with a 50% mortality rate occurring 3 days after TNBS administration. The mechanistic basis of these observations suggests that the anti-inflammatory effects of MOR in the colon are mediated through the regulation of cytokine production and T cell proliferation, two important immunologic events required for the development of colon inflammation in mice and patients with inflammatory bowel disease (IBD). These data provide evidence that MOR plays a role in the control of gut inflammation and suggest that MOR agonists might be new therapeutic molecules in IBD.
AuthorsDavid Philippe, Laurent Dubuquoy, Hervé Groux, Valérie Brun, Myriam Tran Van Chuoï-Mariot, Claire Gaveriaux-Ruff, Jean-Frédéric Colombel, Brigitte L Kieffer, Pierre Desreumaux
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 111 Issue 9 Pg. 1329-38 (May 2003) ISSN: 0021-9738 [Print] United States
PMID12727924 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cytokines
  • Narcotic Antagonists
  • Oligopeptides
  • Receptors, Opioid, mu
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
  • tyrosyl-arginyl-phenylalanyl-lysinamide
  • Naloxone
  • Trinitrobenzenesulfonic Acid
  • Peroxidase
Topics
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • CD4-Positive T-Lymphocytes (metabolism)
  • Colitis (chemically induced, drug therapy, mortality, pathology)
  • Colon (drug effects, immunology, pathology)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)- (pharmacology, therapeutic use)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, SCID
  • Naloxone (pharmacology)
  • Narcotic Antagonists (pharmacology)
  • Oligopeptides (pharmacology, therapeutic use)
  • Peroxidase (metabolism)
  • Receptors, Opioid, mu (agonists, genetics, physiology)
  • Trinitrobenzenesulfonic Acid (toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: